Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Research

Background:

• Adrenocortical carcinoma (ACC) is a rare cancer with frequent recurrence.
• Circulating tumor DNA (ctDNA) is a promising blood-based biomarker for cancer management.
• The utility of ctDNA in ACC patient care is not well-established.

Purpose of the Study:

• To evaluate the real-world application of ctDNA testing in adrenocortical carcinoma patients.
• To assess the correlation between ctDNA levels and imaging-based tumor burden.
• To determine the diagnostic accuracy of ctDNA for detecting ACC disease status.

Main Methods:

• Retrospective analysis of 20 ACC patients undergoing ctDNA testing using a personalized, tumor-informed assay.
• Correlation of ctDNA results with concurrent imaging and clinical evaluation of disease status.
• Statistical analysis to determine sensitivity, specificity, and association with tumor burden.

Main Results:

• ctDNA detection was strongly associated with the presence of disease (OR=74).
• The ctDNA assay demonstrated high sensitivity (88%), specificity (91.7%), and accuracy (88.5%).
• ctDNA levels showed a significant positive correlation with tumor burden (Spearman R=0.844, p<0.001).

Conclusions:

• ctDNA testing is a valuable tool for monitoring adrenocortical carcinoma.
• ctDNA analysis can accurately reflect disease status and tumor burden in ACC.
• ctDNA may facilitate a more personalized approach to adrenocortical carcinoma management.